This is the first meta-analysis to evaluate the efficacy and safety of immune checkpoint inhibitors, including PD-1, PD-L1, and CTLA-4 antibodies, as therapeutic options for colorectal cancer. The gene discussed is PDCD1; the disease is colorectal cancer.